Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 21 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  2. US 10457725

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  3. US 10442864

    Anti-Tie2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  4. US 10442856

    Methods of treating obesity with anti-ANGPTL8 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted
  5. US 10435473

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  6. US 10426848

    Humanized FcγR mice

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  7. US 10428135

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  8. US 10428157

    Dosing regimens for use with PCSK9 inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  9. US 10426146

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  10. US 10421804

    Anti-Zika virus antibodies and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  11. US 10406226

    Method of manufacturing VEGF antagonist fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  12. US 10406222

    Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  13. US 10400036

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  14. US 10400025

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  15. US 10392430

    Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  16. US 10392432

    Human antibodies to influenza hemagglutinin

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  17. US 10390522

    Non-human animals having a humanized programmed cell death 1 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  18. US 10392439

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  19. US 10377817

    Human antibodies to GREM1

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted
  20. US 10370449

    Methods for treating skin infection by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted
  21. US 10358495

    Anti-LAG3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted
  22. US 10358487

    Anti-ANGPTL3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted
  23. US 10342876

    Process for reducing subvisible particles in a pharmaceutical formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  24. US 10316105

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted